Chemistry:Metelimumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 1 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.[1] It was dropped from further development in favour of fresolimumab,[2] which was being developed by Genzyme as of 2006.[3]
History
Metelimumab was isolated by Cambridge Antibody Technology (CAT) using its phage display technology. In 2000, CAT signed a collaborative deal with Genzyme to further develop TGF beta antibodies.[4][5]
In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]
Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab,[2] which was being developed by Genzyme as of 2006.[3]
References
- ↑ "Metelimumab: Agent for scleroderma prop inn human anti-TGF-β1 monoclonal antibody.". Drugs of the Future 29 (11): 1081–3. 2004. doi:10.1358/dof.2004.029.11.860002.
- ↑ 2.0 2.1 CAT may abandon skin drug after trial results disappoint. 10 February 2004. https://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-5354688.html.
- ↑ 3.0 3.1 "Tasidotin". Genzyme. 2006. http://www.genzymeoncology.com/onc/research/onc_p_research.asp.
- ↑ "Genzyme General and Cambridge Antibody Technology To Collaborate on Development of Human Anti-TGF-beta Monoclonal Antibodies". PR News Wire. http://prnwire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-28-2000/0001324438&EDATE=.
- ↑ "Cambridge Antibody, Genzyme to collaborate on human anti-TGFBeta monoclonals". Drug Discovery Online. 2 October 2000. http://www.drugdiscoveryonline.com/article.mvc/Cambridge-Antibody-Genzyme-to-collaborate-on-0001?VNETCOOKIE=NO.
- ↑ "CAT-192 is safe but efficacy in doubt". The Pharma Letter. 16 February 2002. https://www.thepharmaletter.com/article/cat-192-is-safe-but-efficacy-in-doubt.
- ↑ Clinical trial number NCT00043706 for "Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis" at ClinicalTrials.gov
 |  |
